What's Going On With Viking Therapeutics Stock On Tuesday?
Portfolio Pulse from Vandana Singh
Viking Therapeutics Inc (NASDAQ:VKTX) released 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in patients with non-alcoholic steatohepatitis (NASH). The study achieved its primary and secondary endpoints, showing significant improvements in liver fat content, NASH resolution, and fibrosis improvement. VKTX shares are up 5.19% in premarket trading.
June 04, 2024 | 2:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viking Therapeutics released positive 52-week data from its Phase 2b VOYAGE study of VK2809 in NASH patients, achieving primary and secondary endpoints. Shares are up 5.19% in premarket trading.
The positive data from the Phase 2b VOYAGE study indicates significant progress in the treatment of NASH, which is a major market. The achievement of primary and secondary endpoints is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100